Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease

Completed · Phase 2

Conditions studied: Anemia, Hemolytic, Autoimmune, Felty Syndrome, Purpura, Thrombocytopenic, Autoimmune Diseases

In brief

OBJECTIVES: I. Determine the response rate and 1-year event-free survival in patients with severe autoimmune hematologic disease treated with high-dose cyclophosphamide.

Key facts

Study ID

NCT00010387

Run by

Johns Hopkins University

People needed

32

Starts

1999-03-01

Last updated by the study team

2008-09-10

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Johns Hopkins Oncology Center — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.